The U.S. Department of Defense has invested heavily in concepts to continuously monitor performance and health status. While these investments have struggled to reach deployment, the fundamental research barriers are now better. Learning from past failures, the development path is clearer and involves adapting animal-proven biosensors onto commercially deployed, wearable, continuous glucose meters. New investments can focus less on platform development and reliable body access and more on the specific remaining challenges for each use case and biomarker. With a lower risk and lower investment path, continuous wearable monitoring of performance and health is now a closer, investable, and fruitful endeavor. This seminar will cover the following:
- Physiology—why interstitial fluid is the clear front runner for biomarker access.
- Biochemistry—why aptamers are the most believable platform approach.
- Technology—the critical role of commercially available glucose monitors.
- Applications—the remaining application-specific challenges and investments required.